Karol E. Watson

Jan 14, 2025 | jwatch.org | Karol E. Watson

Nov 22, 2024 | healio.com | Erin T. Welsh |Richard Smith |Stephen Nicholls |Karol E. Watson

Obicetrapib tied to sizable LDL lowering on top of other therapies in high-risk patients• In patients with genetic high cholesterol on other therapies, obicetrapib lowered LDL by about 40% vs. placebo. • Obicetrapib also improved other lipid parameters such as lipoprotein(a).

Nov 20, 2024 | jwatch.org | Karol E. Watson

Karol E. Watson, MD, PhD, FACC, reviewing In a randomized trial, spironolactone did not reduce risk for adverse cardiovascular events after MI. Mineralocorticoid receptor antagonists (MRAs) reduce morbidity and mortality in patients with heart failure and in those with acute myocardial infarction (MI) who have left ventricular (LV) systolic dysfunction.

Nov 13, 2024 | jwatch.org | Karol E. Watson

Karol E. Watson, MD, PhD, FACC, reviewing Observational data confirm an association between longer time in target range and reduced incidence of CVD and premature death. In patients with hypertension, the proportion of time in which blood pressure (BP) is outside of the targeted range has been associated with adverse cardiovascular events and mortality in post hoc analyses of clinical trials. A recent prospective cohort study provides data from a real-world setting.

Oct 31, 2024 | jwatch.org | Karol E. Watson

Karol E. Watson, MD, PhD, FACC, reviewing While clinicians cannot modify effects of older age and comorbidities, they can advocate for early revascularization, associated with lower mortality. Cardiogenic shock is a deadly condition, with some studies showing early mortality over 50%.